



# GenStar小分子系列产品—— 抗体抑制剂

部分产品



抗体抑制剂是一类能够通过特定抗原结合并阻断其生物活性，从而抑制特定分子或细胞过程的抗体。抗体抑制剂具有与原始治疗性抗体相同的活性生物成分，可作为阳性对照用于药物效果评价等相关科学研究，同时也可以辅佐验证靶点蛋白的功能活性。**GenStar 现提供数百种抗体抑制剂助力科研工作者，包括鼠源抗体、嵌合抗体、人源抗体、双特异性抗体等，涉及一些热门靶蛋白 PD-L1、PD-1、VEGF、EGFR、HER2、TNF- $\alpha$ 、CD20、Claudin18.2、CTLA4、CD3、CD47、4-1BB 等。**

## 部分产品目录

| 货号      | 英文名称         | CAS号         | 规格          | 纯度    |
|---------|--------------|--------------|-------------|-------|
| MC00001 | Cetuximab    | 205923-56-4  | 1 mg/1 mg*5 | ≥ 99% |
| MC00002 | Nivolumab    | 946414-94-4  | 1 mg/1 mg*5 | ≥ 99% |
| MC00004 | Durvalumab   | 1428935-60-7 | 1 mg/1 mg*5 | ≥ 98% |
| MC00005 | Fresolimumab | 948564-73-6  | 1 mg/1 mg*5 | ≥ 98% |
| MC00006 | Ganitumab    | 905703-97-1  | 1 mg/1 mg*5 | ≥ 99% |
| MC00007 | Ipilimumab   | 477202-00-9  | 1 mg/1 mg*5 | ≥ 99% |
| MC00008 | Mirvetuximab | 1453084-36-0 | 1 mg/1 mg*5 | ≥ 98% |
| MC00009 | Ponsegromab  | 2368950-15-4 | 1 mg/1 mg*5 | ≥ 99% |
| MC00010 | Risankizumab | 1612838-76-2 | 1 mg/1 mg*5 | ≥ 99% |
| MC00011 | Trastuzumab  | 180288-69-1  | 1 mg/1 mg*5 | ≥ 99% |
| MC00012 | Vedolizumab  | 943609-66-3  | 1 mg/1 mg*5 | ≥ 98% |
| MC00013 | Milatumab    | 899796-83-9  | 1 mg/1 mg*5 | ≥ 98% |
| MC00014 | Rituximab    | 174722-31-7  | 1 mg/1 mg*5 | ≥ 99% |
| MC00015 | Seribantumab | 1334296-12-6 | 1 mg/1 mg*5 | ≥ 95% |

## 部分产品目录

| 货号      | 英文名称          | CAS号         | 规格          | 纯度    |
|---------|---------------|--------------|-------------|-------|
| MC00016 | Lusvertikimab | 2375835-91-7 | 1 mg/1 mg*5 | ≥ 99% |
| MC00017 | Andecaliximab | 1518996-49-0 | 1 mg/1 mg*5 | ≥ 98% |
| MC00018 | Daclizumab    | 152923-56-3  | 1 mg/1 mg*5 | ≥ 99% |
| MC00021 | Infliximab    | 170277-31-3  | 1 mg/1 mg*5 | ≥ 99% |
| MC00022 | Ladiratuzumab | 1629760-28-6 | 1 mg/1 mg*5 | ≥ 99% |
| MC00024 | Palivizumab   | 188039-54-5  | 1 mg/1 mg*5 | ≥ 99% |
| MC00025 | Pembrolizumab | 1374853-91-4 | 1 mg/1 mg*5 | ≥ 98% |
| MC00026 | Pertuzumab    | 380610-27-5  | 1 mg/1 mg*5 | ≥ 98% |
| MC00027 | Relatlimab    | 1673516-98-7 | 1 mg/1 mg*5 | ≥ 99% |
| MC00028 | Sabatolimab   | 2252262-24-9 | 1 mg/1 mg*5 | ≥ 98% |
| MC00029 | Tesnatlimab   | 2242758-08-1 | 1 mg/1 mg*5 | ≥ 99% |
| MC00030 | Secukinumab   | 1229022-83-6 | 1 mg/1 mg*5 | ≥ 99% |
| MC00031 | Telisotuzumab | 1781223-80-0 | 1 mg/1 mg*5 | ≥ 99% |
| MC00032 | Vesencumab    | 1205533-60-3 | 1 mg/1 mg*5 | ≥ 99% |
| MC00033 | Cudarolimab   | 2244739-29-3 | 1 mg/1 mg*5 | ≥ 99% |
| MC00034 | Ligufalimab   | 2428381-55-7 | 1 mg/1 mg*5 | ≥ 98% |
| MC00035 | Natalizumab   | 189261-10-7  | 1 mg/1 mg*5 | ≥ 98% |
| MC00036 | Empasiprubart | 2579031-19-7 | 1 mg/1 mg*5 | ≥ 98% |
| MC00037 | IMAB027       | 1650599-68-0 | 1 mg/1 mg*5 | ≥ 99% |
| MC00038 | Isatuximab    | 1461640-62-9 | 1 mg/1 mg*5 | ≥ 98% |
| MC00039 | Teplizumab    | 876387-05-2  | 1 mg/1 mg*5 | ≥ 99% |
| MC00040 | Tocilizumab   | 375823-41-9  | 1 mg/1 mg*5 | ≥ 99% |
| MC00041 | Felzartamab   | 2197112-39-1 | 1 mg/1 mg*5 | ≥ 96% |
| MC00042 | Tilvestamab   | 2226775-26-2 | 1 mg/1 mg*5 | ≥ 97% |
| MC00043 | Atezolizumab  | 1380723-44-3 | 1 mg/1 mg*5 | ≥ 99% |
| MC00044 | Sintilimab    | 2072873-06-2 | 1 mg/1 mg*5 | ≥ 98% |
| MC00046 | Mezagitamab   | 2227490-52-8 | 1 mg/1 mg*5 | ≥ 99% |
| MC00047 | Xentuzumab    | 1417158-65-6 | 1 mg/1 mg*5 | ≥ 98% |
| MC00048 | Adalimumab    | 331731-18-1  | 1 mg/1 mg*5 | ≥ 98% |
| MC00049 | Anetumab      | 1954758-84-9 | 1 mg/1 mg*5 | ≥ 98% |
| MC00050 | Canakinumab   | 914613-48-2  | 1 mg/1 mg*5 | ≥ 99% |
| MC00051 | Denosumab     | 615258-40-7  | 1 mg/1 mg*5 | ≥ 97% |
| MC00052 | Evolocumab    | 1256937-27-5 | 1 mg/1 mg*5 | ≥ 97% |
| MC00053 | Guselkumab    | 1350289-85-8 | 1 mg/1 mg*5 | ≥ 98% |
| MC00054 | Omalizumab    | 242138-07-4  | 1 mg/1 mg*5 | ≥ 98% |
| MC00055 | Panitumumab   | 339177-26-3  | 1 mg/1 mg*5 | ≥ 98% |
| MC00056 | Patritumab    | 1262787-83-6 | 1 mg/1 mg*5 | ≥ 99% |
| MC00057 | Prezalumab    | 1523164-68-2 | 1 mg/1 mg*5 | ≥ 98% |
| MC00058 | Siltuximab    | 541502-14-1  | 1 mg/1 mg*5 | ≥ 99% |
| MC00059 | Tremelimumab  | 745013-59-6  | 1 mg/1 mg*5 | ≥ 99% |
| MC00060 | Zolbetuximab  | 1496553-00-4 | 1 mg/1 mg*5 | ≥ 99% |
| MC00061 | Sarilumab     | 1189541-98-7 | 1 mg/1 mg*5 | ≥ 99% |
| MC00062 | Elotuzumab    | 915296-00-3  | 1 mg/1 mg*5 | ≥ 98% |
| MC00063 | Pamrevlumab   | 946415-13-0  | 1 mg/1 mg*5 | ≥ 99% |
| MC00064 | Romosozumab   | 909395-70-6  | 1 mg/1 mg*5 | ≥ 97% |
| MC00065 | Bimagrumab    | 1356922-05-8 | 1 mg/1 mg*5 | ≥ 98% |
| MC00066 | Utomilumab    | 1417318-27-4 | 1 mg/1 mg*5 | ≥ 98% |
| MC00067 | Nipocalimab   | 2211985-36-1 | 1 mg/1 mg*5 | ≥ 98% |
| MC00068 | Abciximab     | 143653-53-6  | 1 mg/1 mg*5 | ≥ 99% |
| MC00069 | Envafohimab   | 2102192-68-5 | 1 mg/1 mg*5 | ≥ 99% |
| MC00070 | Barzolvolimab | 2438203-51-9 | 1 mg/1 mg*5 | ≥ 99% |
| MC00071 | Oleclumab     | 1803176-05-7 | 1 mg/1 mg*5 | ≥ 99% |
| MC00072 | Sotevtamab    | 2411526-47-9 | 1 mg/1 mg*5 | ≥ 97% |
| MC00073 | Lucatumumab   | 903512-50-5  | 1 mg/1 mg*5 | ≥ 99% |

